Cargando…
Emerging SARS-CoV-2 variant B.1.1.7 reduces neutralisation activity of antibodies against wild-type SARS-CoV-2
Spike-specific antibodies contribute significantly to the neutralising activity against SARS-CoV-2 and are important for the therapeutic effect of convalescent plasma. B.1.1.7 is a recently emerged variant of SARS-CoV-2 that has several mutations in the gene encoding for the spike-protein. To assess...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Author(s). Published by Elsevier B.V.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8282447/ https://www.ncbi.nlm.nih.gov/pubmed/34298379 http://dx.doi.org/10.1016/j.jcv.2021.104912 |
_version_ | 1783723015941390336 |
---|---|
author | Müller, Katharina Girl, Philipp Giebl, Andreas von Buttlar, Heiner Dobler, Gerhard Bugert, Joachim J. Gruetzner, Stefanie Wölfel, Roman |
author_facet | Müller, Katharina Girl, Philipp Giebl, Andreas von Buttlar, Heiner Dobler, Gerhard Bugert, Joachim J. Gruetzner, Stefanie Wölfel, Roman |
author_sort | Müller, Katharina |
collection | PubMed |
description | Spike-specific antibodies contribute significantly to the neutralising activity against SARS-CoV-2 and are important for the therapeutic effect of convalescent plasma. B.1.1.7 is a recently emerged variant of SARS-CoV-2 that has several mutations in the gene encoding for the spike-protein. To assess the potential effect these mutations could have on the neutralising efficacy of antibodies, we evaluated 96 serum samples from convalescent plasma donors collected before the first occurrence of B.1.1.7 and tested their neutralising effect on wild-type SARS-CoV-2 and B.1.1.7. We found that B.1.1.7 is more resistant to neutralisation by convalescent plasma from patients infected with wild-type SARS-CoV-2 with an overall decrease in neutralising activity of 47.7%. Thus, the neutralising effect of convalescent plasma should be determined against the major circulating virus clades whenever possible to ensure the best possible therapeutic effect. |
format | Online Article Text |
id | pubmed-8282447 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | The Author(s). Published by Elsevier B.V. |
record_format | MEDLINE/PubMed |
spelling | pubmed-82824472021-07-20 Emerging SARS-CoV-2 variant B.1.1.7 reduces neutralisation activity of antibodies against wild-type SARS-CoV-2 Müller, Katharina Girl, Philipp Giebl, Andreas von Buttlar, Heiner Dobler, Gerhard Bugert, Joachim J. Gruetzner, Stefanie Wölfel, Roman J Clin Virol Article Spike-specific antibodies contribute significantly to the neutralising activity against SARS-CoV-2 and are important for the therapeutic effect of convalescent plasma. B.1.1.7 is a recently emerged variant of SARS-CoV-2 that has several mutations in the gene encoding for the spike-protein. To assess the potential effect these mutations could have on the neutralising efficacy of antibodies, we evaluated 96 serum samples from convalescent plasma donors collected before the first occurrence of B.1.1.7 and tested their neutralising effect on wild-type SARS-CoV-2 and B.1.1.7. We found that B.1.1.7 is more resistant to neutralisation by convalescent plasma from patients infected with wild-type SARS-CoV-2 with an overall decrease in neutralising activity of 47.7%. Thus, the neutralising effect of convalescent plasma should be determined against the major circulating virus clades whenever possible to ensure the best possible therapeutic effect. The Author(s). Published by Elsevier B.V. 2021-09 2021-07-16 /pmc/articles/PMC8282447/ /pubmed/34298379 http://dx.doi.org/10.1016/j.jcv.2021.104912 Text en © 2021 The Author(s). Published by Elsevier B.V. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | Article Müller, Katharina Girl, Philipp Giebl, Andreas von Buttlar, Heiner Dobler, Gerhard Bugert, Joachim J. Gruetzner, Stefanie Wölfel, Roman Emerging SARS-CoV-2 variant B.1.1.7 reduces neutralisation activity of antibodies against wild-type SARS-CoV-2 |
title | Emerging SARS-CoV-2 variant B.1.1.7 reduces neutralisation activity of antibodies against wild-type SARS-CoV-2 |
title_full | Emerging SARS-CoV-2 variant B.1.1.7 reduces neutralisation activity of antibodies against wild-type SARS-CoV-2 |
title_fullStr | Emerging SARS-CoV-2 variant B.1.1.7 reduces neutralisation activity of antibodies against wild-type SARS-CoV-2 |
title_full_unstemmed | Emerging SARS-CoV-2 variant B.1.1.7 reduces neutralisation activity of antibodies against wild-type SARS-CoV-2 |
title_short | Emerging SARS-CoV-2 variant B.1.1.7 reduces neutralisation activity of antibodies against wild-type SARS-CoV-2 |
title_sort | emerging sars-cov-2 variant b.1.1.7 reduces neutralisation activity of antibodies against wild-type sars-cov-2 |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8282447/ https://www.ncbi.nlm.nih.gov/pubmed/34298379 http://dx.doi.org/10.1016/j.jcv.2021.104912 |
work_keys_str_mv | AT mullerkatharina emergingsarscov2variantb117reducesneutralisationactivityofantibodiesagainstwildtypesarscov2 AT girlphilipp emergingsarscov2variantb117reducesneutralisationactivityofantibodiesagainstwildtypesarscov2 AT gieblandreas emergingsarscov2variantb117reducesneutralisationactivityofantibodiesagainstwildtypesarscov2 AT vonbuttlarheiner emergingsarscov2variantb117reducesneutralisationactivityofantibodiesagainstwildtypesarscov2 AT doblergerhard emergingsarscov2variantb117reducesneutralisationactivityofantibodiesagainstwildtypesarscov2 AT bugertjoachimj emergingsarscov2variantb117reducesneutralisationactivityofantibodiesagainstwildtypesarscov2 AT gruetznerstefanie emergingsarscov2variantb117reducesneutralisationactivityofantibodiesagainstwildtypesarscov2 AT wolfelroman emergingsarscov2variantb117reducesneutralisationactivityofantibodiesagainstwildtypesarscov2 |